Canopy Growth Corporation
Canopy Growth Corporation is a world leading diversified Canadian cannabis company. It operates a collection of diverse brands and curated strain varieties, supported by over half a million square feet of indoor and greenhouse production capacity.
AusCann and Canopy Growth Corporation (TSE:WEED), are working to become the leading suppliers of medicinal cannabis products to the Australian market. In April 2018, AusCann announced that it had received an import permit under its existing licence to receive cannabis oils from its major shareholder, Canopy.
AusCann will initially import Canopy-supplied AusCann-branded products for chronic and neuropathic pain. Canopy and AusCann are also working on an arrangement in which Canopy will also supply Spectrum Cannabis branded products for AusCann to distribute into the Australian market alongside existing complementary AusCann products. Spectrum Cannabis is Canopy Growth’s international medical brand, operating under a simple colour-coded system to classify its medicinal cannabis products. For more information, see here.
Fundacion Daya is a non-profit Chilean organisation. Its objective is research and promotion of medicinal cannabis, aimed at relieving human suffering as well as advising on the design of public policies that promote the physical and well-being of people. The foundation's therapists advise patients about the use of medicinal cannabis and the different avenues of access to these therapies.
In 2016, Fundacion Daya and AusCann’s formed a joint venture known as DayaCann. In April 2017, DayaCann harvested its first crop, yielding over 300kg of dried cannabis buds.
Phytoplant Research is a privately-owned Spanish company founded in 2008. The company specialises in developing the industrial chain of medicinal plants, from selection and breeding to registration, cultivation of registered varieties and obtaining derived products. Phytoplant Research focuses on research and development products that contain plant material and extracts, as well as essential and seed oils. These products represent significant economic potential for the pharmaceutical, nutraceutical and dermocosmetic industries.
AusCann accesses genetics, breeding, cultivation and extraction expertise from PhytoPlant.
Zelda Therapeutics is a California-founded biotechnology company focused on medical cannabis therapies with a strong Australian connection. Zelda has exclusive access to a substantial patient data set that demonstrates clinical efficacy of proprietary formulations in a range of diseases. Zelda was formed to fund clinical efficacy trials at leading clinical research organisations around the world based and through this data it can advance straight to clinical trials.
Zelda Therapeutics has signed an agreement with AusCann for the supply of medical grade cannabis for its Australian based trials.
Murdoch University is a public university in Perth, Western Australia, with campuses also in Singapore and Dubai. It is internationally recognised as a research-led institution with a flexible approach to learning.
AusCann have partnered with Murdoch University in a R&D collaboration for development of additional cannabis strains, with Phytoplant also contributing and further developing their strains.
Western Australian State Agricultural Biotechnology Centre (SABC)
The SABC is the collaborative university Centre for R&D in agricultural and veterinary biotechnology in Western Australia based at Murdoch University. It provides platform technologies and world class equipment and facilities for R&D in agricultural biotechnology to researchers from universities, state government and industry. Through AusCann’s research and development collaboration with Murdoch University to cultivate and develop targeting medical cannabis strains it will be working closely with the SABC’s team, led by Professor Mike Jones, and will have access to its state-of-the-art facilities.